Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.11Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: 6.09%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for ARS Pharmaceuticals, highlighted by the successful launch and growing adoption of neffy, substantial payer coverage progress, and strong financial positioning. However, challenges with prior authorizations and delays in some payer formulary additions present obstacles that need addressing. Overall, the company is well-placed for significant growth, with strategies to overcome existing challenges.Company Guidance
In the recent call, ARS Pharmaceuticals announced significant progress and guidance for the upcoming year. The company reported $7.3 million in net product revenue for neffy since its U.S. launch, with expectations for a strong sales trajectory as they aim for at least 80% commercial coverage by summer 2025. Neffy addresses a $3 billion market opportunity with 6.5 million U.S. patients prescribed epinephrine, and ARS aims to capture additional market segments worth over $7 billion. The recent FDA approval for the 1 mg dose, targeting children weighing 15 to less than 30 kg, is expected to boost market penetration, especially during the back-to-school season. ARS has secured payer agreements with major organizations like Caremark, UnitedHealthcare, and OptumRx, ensuring no prior authorization is needed for 51% of commercially insured patients, with plans to reach 80% by early summer. The company holds a robust cash position of over $314 million, supporting a planned $40-50 million direct-to-consumer campaign to increase awareness and adoption. Global expansion efforts are also underway, with submissions and approvals anticipated in key markets including the EU, UK, Canada, Japan, and China.Successful Launch of Neffy
In September, ARS successfully launched neffy 2 milligrams in the United States and secured FDA approval for the 1 milligram dose for children weighing 15 to less than 30 kilograms.
Strong Payer Coverage Progress
As of April 1, over 51% of commercially insured patients can get neffy without prior authorization, with expectations of over 80% coverage by early summer.
Significant Revenue and Growth
Neffy generated $7.3 million in net product revenue since its launch, reflecting strong early adoption and prescribing by thousands of health care providers.
Positive Clinical Feedback
At the 2025 Quad AI meeting, numerous physicians shared successful real-world experiences with neffy, reinforcing its acceptance as the new standard of care.
Strong Financial Position
ARS ended the year with over $314 million in cash and equivalents, allowing for further investment in neffy's commercialization.
---
SPRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SPRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $11.65 | $14.31 | +22.83% |
| Nov 13, 2024 | $16.61 | $14.08 | -15.23% |
| Aug 06, 2024 | $9.78 | $9.56 | -2.25% |
| May 09, 2024 | $8.80 | $8.74 | -0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ARS Pharmaceuticals (SPRY) report earnings?
ARS Pharmaceuticals (SPRY) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is ARS Pharmaceuticals (SPRY) earnings time?
ARS Pharmaceuticals (SPRY) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRY EPS forecast?
SPRY EPS forecast for the fiscal quarter 2025 (Q1) is -0.3.
---